Andrea Sambatti – General Manager, Boehringer Ingelheim Sweden

09.07.2019
Andrea Sambatti is the general manager of Boehringer Ingelheim (BI) Sweden and is a member of the board of directors for LIF. Sambatti discusses how Sweden is a testbed for innovation and often one of the first places where pharma companies launch their products. She also discusses how Sweden is at the forefront of digitalization within healthcare and her experiences of working for BI in Brazil and Germany.  
Sweden is used as a testing ground for pilot products and is one of the first countries where we launch products
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Sweden, Digitalization, Boehringer Ingelheim, Strategy, Innovation

Related Interviews

Anders Millerhovf – CEO, CTC Clinical Trial Consultants, Sweden

In a fast-changing Nordic CRO industry, CTC Clinical Trial Consultants has opted to differentiate with a unique one-stop-shop approach. CEO Anders Millerhovf reveals how the relatively young company has managed…

Jan Hellqvist – General Manager, KLIFO Sweden

With almost three decades of experience in the Swedish life science industry, Jan Hellqvist, general manager of KLIFO in Sweden, explains why the country has seen the number of clinical…

Martina Stenerdal – General Manager, PPD Scandinavia

As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year…

Related Articles

Nordics / Danish-Swedish Clinical Trial Collaboration: Better Together?

Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…

Europe / Sustainability & Pharma Procurement: Are You ‘Green’ Enough? 

In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…

Sweden / A Global Testbed for AMR Incentive Models

Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…

Latest Report

Saudi Arabia Pharma Report 2022

Related Content

Sweden
Digitalization
Boehringer Ingelheim
Strategy
Innovation